XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Disaggregates Our Revenues by Major Source (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue Recognition [Line Items]        
Revenues $ 64,153,000 $ 56,191,000 $ 116,455,000 $ 109,475,000
Biopharma/Pharma [Member]        
Revenue Recognition [Line Items]        
Revenues 51,728,000 45,489,000 94,739,000 87,877,000
Animal Health [Member]        
Revenue Recognition [Line Items]        
Revenues 9,562,000 8,394,000 16,356,000 17,394,000
Reproductive Medicine [Member]        
Revenue Recognition [Line Items]        
Revenues $ 2,863,000 $ 2,308,000 $ 5,360,000 $ 4,204,000